Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSMOS: Oral to Subcutaneous Methotrexate and MTX-PG Levels in MTX-Naive RA
jRCT1031240633Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of methotrexate in rheumatoid arthritis (RA), sponsored by Eisai Co., Ltd. Primary endpoint: Change in erythrocyte MTX-PG concentrations from baseline. Started Apr 2025; status: recruiting.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT1031240633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240633.